How Dr. Clay Siegall has impacted Cancer Research and Therapy
An Overview of Clay Siegall
You may be wondering why Clay has that relent pursuit in cancer research and therapies. His determination emanates from the fact that he knows the pains and losses that cancer brings given that his father was diagnosed with brain cancer when he only nineteen. Sometimes Siegall would accompany his father for the therapies and get an opportunity to ask the oncologists many questions like where they would get their tools and how they would know which drug to use among other queries. His inquisitive nature is what became a driving force to go to graduate school to study and do research on the medicines that he would give oncologists to use in pursuit of the cure for cancer.
The academic Journey of Clay Siegall
Currently, Clay is a Ph.D. Holder from George Washington University which works in close collaboration with National Institute of Health where he undertook his internship. Following his graduation, he returned to NIH for a two-year post-doctoral fellowship in a full-time position. That provided him with an opportunity to publish his papers that related to cancer research. These research papers attracted many offers from pharmaceutical companies. However, he turned down most of the offers as some of them would derail him from his career path whose focus was in line with cancer therapies.
Interestingly, there was one company whose offer was in line with his career goals, and he would not deny himself that opportunity to work with the company as their concentration was also cancer therapies.
Seattle Genetics Inc.
Clay Siegall is the CEO, chairman of the board and the president of the Seattle Genetics Inc. that offers cancer therapy. The company offers twelve cancer medications and one approved product called Adcentris.
Clay suggests that standard cancer treatment is such that it destroys the dividing cells regardless of whether they are healthy or not.
However, for his research therapies, he divides the treatments into three: that which focuses on the immune system, another whose target is inside the cell and the final one which targets outside the cell. Thus, for the therapy he offers, through Seattle Genetics, he spares the healthy cells which is a great stride in cancer research. There is indeed great hope for the entire world when we have dedicated people like Clay Siegall who will provide a breakthrough in the study of cancer. Everyone remains indebted for the sacrifices of such people.